FDA OKs expanded use of Lilly’s Taltz

The FDA approves the use of Eli Lilly’s (NYSE:LLY) Taltz (ixekizumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpa) in patients with objective signs of inflammation, the sixth indication approved in the U.S. for the IL-17A antagonist.

Nr-axSpa is a type of arthritis affecting the spine and sacroiliac joints.

The FDA approved the use of the med in radiographic axial spondyloarthritis in August 2019.

https://seekingalpha.com/news/3578899-fda-oks-expanded-use-of-lillys-taltz